STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 204.6

Change

-2.30 (-1.11)%

Market Cap

USD 0.66B

Volume

126.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-22 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

+0.06 (+0.13%)

USD 56.03B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-5.50 (-1.05%)

USD 13.60B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

-3.37 (-0.90%)

USD 11.29B
WRD:PA HSBC MSCI World UCITS ETF

-0.31 (-0.90%)

USD 11.04B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-1.69 (-0.64%)

USD 10.45B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-3.60 (-0.78%)

USD 7.99B
WLD:PA Lyxor UCITS MSCI World D-EUR

-2.85 (-0.84%)

USD 7.49B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

-0.10 (-1.48%)

USD 7.42B
HHH:PA HSBC S&P 500 UCITS ETF

-0.57 (-1.07%)

USD 7.22B
SPY4:PA SSgA SPDR S&P 400 US Mid Cap

-1.20 (-1.46%)

USD 5.38B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.34% 30% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.34% 29% F 35% F
Trailing 12 Months  
Capital Gain -10.07% 6% D- 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.07% 6% D- 30% F
Trailing 5 Years  
Capital Gain 23.72% 28% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.72% 27% F 42% F
Average Annual (5 Year Horizon)  
Capital Gain 9.06% 58% F 65% D
Dividend Return 9.06% 56% F 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.37% 73% C 88% B+
Risk Adjusted Return 108.21% 90% A- 94% A
Market Capitalization 0.66B 70% C- 72% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike